Background and Purpose-This study determined the influence of concomitant antiplatelet therapy (APT) on hematoma characteristics and outcome in primary spontaneous intracerebral hemorrhage (ICH), vitamin K antagonist (VKA)-and non-VKA oral anticoagulant-associated ICH. Methods-Data of retrospective cohort studies and a prospective single-center study were pooled. Functional outcome, mortality, and radiological characteristics were defined as primary and secondary outcomes. Propensity score matching and logistic regression analyses were performed to determine the association between single or dual APT and hematoma volume. Results-A total of 3580 patients with ICH were screened, of whom 3545 with information on APT were analyzed. Three hundred forty-six (32.4%) patients in primary spontaneous ICH, 260 (11.4%) in VKA-ICH, and 30 (16.0%) in non-VKA oral anticoagulant-associated ICH were on APT, and these patients had more severe comorbidities. 
A ntiplatelet therapy (APT) is commonly used and effective in preventing cardiovascular events, 1,2 but its side effects increasingly receive attention. 3, 4 In the general population, APT was previously associated with an increased risk for developing hemorrhagic complications, specifically both extracranial and intracranial hemorrhages. 1 ,2 Yet, these findings are controversial and low-dose aspirin use was not associated with an increased risk of intracerebral hemorrhage (ICH) in a recent observational study. 5 In patients on oral anticoagulation (OAC), the concomitant use of APT was linked to higher absolute rates of hemorrhagic complications; however, the specific risk of ICH was not significantly elevated. 6 Among patients with ICH, concomitant APT was associated with higher in-hospital mortality in OAC-associated but not in primary spontaneous ICH (non-OAC-ICH). 4 To our knowledge, besides these potential effects of APT on ICH occurrence and in-hospital mortality, the influence of APT on ICH characteristics and long-term functional outcome is rather unestablished, specifically in OAC-ICH. Smaller observational studies suggested that APT in non-OAC-ICH may be related to increased intraventricular involvement 7 and hematoma expansion, 8, 9 yet methodological shortcomings leave room for uncertainty. 10, 11 On the contrary, there are essentially no data about APT effects on ICH characteristics in vitamin K antagonist (VKA)-and non-VKA-OAC (NOAC)-associated ICH. The present study explored and compared the influence of APT comedication on hematoma characteristics and functional outcome in patients with (1) primary spontaneous ICH, (2) VKA-associated ICH, and (3) NOAC-associated ICH.
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Methods

Study Design and Patient Selection
The authors declare that all supporting data are available within the article and its online-only Data Supplement. Detailed methods of the RETRACE program (German-Wide Multicenter Analysis of Oral Anticoagulation-Associated Intracerebral Hemorrhage) have been published previously. 12, 13 In brief, we pooled data of 2504 consecutive OAC-ICH patients from retrospective observational German-wide multicenter cohorts at 22 
Definitions
Definition of ICH Classifications and APT
We excluded ICH with secondary pathogeneses, such as trauma, arteriovenous malformation, aneurysms, tumor, acute thrombolysis, or coagulopathies, other than anticoagulation, as well as all patients with recurrent ICH. We defined non-OAC-ICH as bleeding into the parenchyma of the brain not related to secondary ICH pathogeneses or OAC. 14 We defined VKA-ICH as ICH on effective anticoagulation with VKAs indicated by an international normalized ratio value of >1.5 on hospital admission. 15 We defined NOAC-ICH as ICH on treatment with NOAC at ICH onset. 16 Further, we scored whether patients were on standard versus reduced NOAC dosages. 17 We defined APT-ICH as APT medication at onset of ICH. 18 We assessed all available information on APT and noted whether patients received single APT (SAPT; including all monotherapeutic administrations of acetylsalicylic acid, dipyridamole, P2Y 12 platelet receptor inhibitor, or glycoprotein IIb/IIIa inhibitors) or dual APT (in all combinations except for aspirin/dipyridamole, which was scored as SAPT).
Primary and Secondary Outcomes
We defined functional outcome using the modified Rankin Scale (mRS) 19 
Acquisition of Outcome Parameters
Imaging
We evaluated all available cranial computed tomographic and magnetic resonance imaging scans and scored hematoma characteristics (ICH location, intraventricular hemorrhage; primary intraventricular involvement was rated as deep ICH) as described previously. 12 ICH volume was calculated based on hematoma shape. We used the ABC/2 method (A is defined as the largest axial diameter of the hemorrhage, B the diameter 90° to A, and C the craniocaudal diameter of the bleeding) for round-to-ellipsoid and ABC/3 method for irregularly shaped ICH 22, 23 considering conversion models for different imaging modalities. 24, 25 Hematoma enlargement was defined as >33% relative or ≥12.5 cm 3 absolute ICH volume increase from initial to follow-up imaging. 12, 26 To present validity of ICH volume assessment by the ABC/2 formula in the UKER study, we compared ABCmeasured ICH volume with volumetrically assessed ICH volume 27 in a subset of 320 patients with ICH.
Outcome
Follow-up data on mortality and functional outcome (mRS at 3 months) were obtained by standardized mailed questionnaire or semistructured telephone interview.
12
Statistical Analysis
All analyses were performed using the statistical package SPSS 21.0 (www.spss.com) and R 2.12.0 (www.r-project.org). We performed 2-sided statistical tests and set the significance level at α=0.05. Frequency distribution was evaluated by Kolmogorov-Smirnov test. Normally distributed data are expressed as mean (SD) compared using the Student t test, otherwise as median (interquartile range) and compared using the Mann-Whitney U test. For comparison of frequency distribution of categorical variables (presented as counts and percentage in brackets), Pearson χ 2 and the Fisher exact test were used. Univariate analyses were corrected for accumulation of type 1 error after multiple comparisons by Holm sequential Bonferroni procedure. Multiple imputation with fully conditional specification was performed for outcome analysis in the smaller number of NOAC-ICH after appropriate evaluation (Little missing completely at random test) to minimize bias because of missing data. We used the overall cohort of RETRACE II to generate missing outcome data for NOAC-ICH patients. 13, 28, 29 Multivariable binary logistic regression analyses were adjusted for established parameters-age, time from symptom onset to admission, and hematoma location (deep, lobar, cerebellar, and brain stem) 30 -and for parameters identified here to be associated with initial ICH volume (P value, <0.1) in univariate analysis. For further information, see Methods in the online-only Data Supplement.
Results
Study Population and Clinical Characteristics
Among 3580 patients with ICH (2504 OAC-ICH patients from the RETRACE I+II study programs and 1076 non-OAC-ICH patients from the UKER-ICH registry; Tables I and II in were on APT, and those patients presented more often with prior ischemic stroke (P=0.027). Patients with ICH on APT showed higher HAS-BLED scores (based on parameters hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, age and drugs or alcohol) in all 3 groups (P<0.001).
Before analysis of primary and secondary outcomes, in light of the imbalances in baseline clinical characteristics (Table 1) , we performed propensity score matching for all 3 groups (Tables III through V in the online-only Data Supplement) after which all demographic parameters were evenly balanced between patients with and without APT. Residual differences in HAS-BLED scores between patients with and without APT were based on the nature of the HAS-BLED score, calculated including APT. There were also no differences regarding early care limitation, surgical intervention, or external ventricular drain placement ( Table 2 ).
Analysis of Primary and Secondary Outcomes
Primary Outcome and Mortality Functional outcome at 3 months, dichotomized according to APT, is illustrated in Figure 2 In the not propensity score-matched overall cohort, there were significant differences in the proportion of patients with favorable outcome among non-OAC-ICH, VKA-ICH, and NOAC-ICH patients with prior APT (P=0.018; Figure I 
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we compared clinical outcomes in a patient cohort with reduced patient numbers (NOAC-adapted patient numbers in non-OAC-ICH and VKA-ICH), which indicated no power issues (Table  VI and Figure II in the online-only Data Supplement). To more specifically assess functional outcome focusing on survivors only, multivariable analyses confirmed worse functional outcome in VKA-APT-ICH patients only (Table VI and Figure II in the online-only Data Supplement).
Secondary Radiological Outcomes
Regarding both secondary outcomes, that is, baseline hematoma volume and occurrence of hematoma enlargement, there were no significant differences among non-OAC-ICH patients with and without APT (ICH volume, 14. 
Association of APT and Hematoma Volume
Given the differences in ICH volume for OAC-related ICH, we performed multivariable regression analyses corrected for APT indicates antiplatelet therapy; CHA 2 DS 2 -VASc score, based on parameters congestive heart failure, hypertension, age, diabetes mellitus, prior stroke, TIA or thromboembolism, vascular disease, and sex; HAS-BLED score, based on parameters hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, age, and drugs or alcohol; ICH, intracerebral hemorrhage; INR, international normalized ratio; IQR, interquartile range; NA, not applicable; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulant; non-OAC-ICH, not oral anticoagulation-associated intracerebral hemorrhage (ie, primary spontaneous intracerebral hemorrhage); TIA, transient ischemic attack; and VKA, vitamin K antagonist.
confounding variables to verify the association of APT use and hematoma volume for the 3 cohorts (Figure 3) APT indicates antiplatelet therapy; ICH, intracerebral hemorrhage; IQR, interquartile range; NOAC, non-vitamin K antagonist oral anticoagulant; non-OAC-ICH, not oral anticoagulation-associated intracerebral hemorrhage (ie, primary spontaneous intracerebral hemorrhage); and VKA, vitamin K antagonist.
Subanalysis of Anticoagulation Reversal and Platelet Transfusion Management
*Hematoma enlargement was defined as an increase of volume >33% or ≥12.5 cm 3 on follow-up imaging. †Not significant after Bonferroni-Holm correction for multiple comparisons.
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Discussion
To our knowledge, the present study represents the largest analysis of APT influence on hematoma characteristics and long-term functional outcome in patients with primary spontaneous and OAC-associated ICH. As demonstrated here, APT did not influence ICH characteristics or clinical outcomes in non-OAC-ICH. On the contrary, in OAC-ICH, APT was related to increased hematoma volume and worse functional outcome in VKA-ICH but not significantly in NOAC-ICH. These effects were more pronounced in dual APT versus SAPT. Regarding non-OAC-ICH, previous studies reported conflicting data, partly suggesting that APT may be related to increased rates of hematoma enlargement, 8 intraventricular hemorrhage, 7 and mortality. 9, 31 Yet, these results were solely based on observational studies with methodological shortcomings-mainly limited patient numbers [7] [8] [9] and insufficient adjustment for differences in baseline characteristics. 8, 9, 31 Larger studies demonstrated essentially no differences in hematoma characteristics, 10,32 mortality, 4, 10, 18, 33 and functional outcome 10 for SAPT and attributed reported discrepancies to differences in comorbidities and demographics. 18, 33 In line with these studies, results of our study verified absent APT influence on outcome measures in primary spontaneous ICH-a finding also supported by experimental analyses. [34] [35] [36] Regarding OAC-ICH, there were essentially no larger studies evaluating hematoma characteristics or long-term clinical outcome in those patients with concomitant APT. 30, 37 We here demonstrate that in VKA-ICH, APT was associated with more frequent lobar affection, larger hematoma volume, increased mortality, and worse functional outcome. These findings are in line with a recent registry-based study 4 and suggest an additive antihemostatic effect of APT on OAC-related ICH characteristics, as suggested previously for APT patients with lobar OAC-ICH. 30 Given the larger ICH volumes in patients with VKA and APT, the question remains about the therapeutic implication of this finding. Rapid anticoagulation reversal is an essential and established part of VKA-ICH treatment. 12, 14 In the present study, reversal treatment was performed not significantly differently among OAC-ICH patients with and without APT. Further, platelet transfusions have been tested as an alternative treatment option, yet the PATCH trial (Platelet Transfusion Versus Standard Care After Acute Stroke due to Spontaneous Cerebral Haemorrhage Associated With Antiplatelet Therapy) verified not to use platelet infusions in the acute phase of ICH. 38 In line, our data revealed that indeed platelet transfusions were more often given in APT patients, yet there were no significant associations with reduced rates of hematoma enlargement or with clinical outcomes; however patient numbers were small for these subanalyses.
In NOAC-ICH, no previous study analyzed associations of APT with ICH characteristics. As shown here, concomitant APT was nonsignificantly associated with more lobar ICH location, larger hematoma volume, and there were no significant differences in clinical outcomes, neither for standard dosed nor reduced-dose NOAC agents. As the point estimates in the forest plots appear similar to that of VKA-ICH, it remains to be explored in larger studies whether limited patient numbers may explain our findings. In addition, anti-Xa activity and hemoclot levels on admission were not available for all individuals why some NOAC-ICH patients may have had ICH in subtherapeutic NOAC levels. In this regard, a recent meta-analysis provided evidence of decreased incidence rates of intracranial hemorrhage in NOAC compared with VKA patients with concomitant aspirin use, 39 yet without focusing specifically on ICH characteristics. Consistently, we here found an advantage of reduced-dose NOAC over VKA on ICH volume. Regarding SAPT versus dual APT, regularly required, for example, after percutaneous coronary interventions, we noted no increased hematoma volume in those patients on SAPT who suffered from non-OAC-ICH-a finding consistent with experimental studies. 35 On the contrary, a recent registry study reported increased mortality at hospital discharge for those with combined antiplatelet inhibition. 33 The limited patient numbers in our dual APT patient groups leave room for controversy, specifically in NOAC patients. Recent randomized controlled trials conducted for treatment after percutaneous coronary interventions with stenting showed an increased bleeding risk for dual APT versus SAPT in anticoagulated patients. 39, 40 Adding on to this finding, our results now verify that triple therapy in VKA-ICH is moreover related to increased hematoma volumes on admission. Therefore, supporting current guidelines and recent trials results, the combination of OAC and dual APT should be carefully evaluated and reserved for high-risk patients and short time frames.
Our study has several shortcomings. The multicenter part of OAC-ICH patients was based on a retrospective study design and data of non-OAC-ICH patients on a single-center analysis, leading to potential confounding and center effects. ICH volumes were calculated by ABC/2 and ABC/3 method, respectively, but not by volumetric assessment. Rates of hematoma expansion were relatively low. Specific numbers for interrater reliability, measurement of platelet function, and data of cerebral amyloid angiopathy or apolipoprotein E were not available. There were too few patients among the NOAC-ICH group to perform subanalyses on SAPT versus dual APT, especially when stratified for reduced and standard dosages. Although we adjusted for limited NOAC-ICH patient numbers, residual power issues cannot be fully excluded. We also did not obtain anti-Xa activity and hemoclot levels on admission for all NOAC-ICH patients. However, results for the non-OAC-ICH and VKA-ICH groups were based on large cohorts covering the same time period of 10 years, and sound statistical methods were applied to account for imbalances of baseline characteristics. In this regard, it should be mentioned that there has been substantial progress and improvement in routine neurocritical care of patients with ICH during the last decade, which may have introduced bias given the long study period of the present analyses.
Conclusions
In summary, this analysis provides evidence that APT does not affect ICH characteristics and outcome in non-OAC-ICH patients; however, it is associated with larger ICH volume and worse functional outcome in VKA-ICH, presumably by additive antihemostatic effects. Whether APT patients with NOAC-ICH show characteristics similar to VKA-ICH needs to be verified in larger analyses, preferable obtained in a prospectively randomized setting. Our data further argue in disfavor of triple therapies because ICH characteristics, and corresponding functional outcome, appear the worst in these patients.
